Grant of Awards

Summary by AI BETAClose X

Oxford Biomedica PLC announced on April 8, 2026, the grant of nil-cost share options under its 2024 Long Term Incentive Plan and Deferred Bonus Plan to several senior executives, including Dr. Frank Mathias and Dr. Lucinda Crabtree. These grants, effective April 7, 2026, are part of the re-instatement of originally intended award levels and are subject to performance conditions and post-vesting holding periods. The 2026 LTIP metrics are set at 60% revenue and 40% Operating EBITDA margin, assessed on a constant currency basis.

Disclaimer*

UK 100

Latest directors dealings